Ketamine therapy
Ketamine is an FDA-approved anesthetic that clinicians also prescribe off-label for depression, most often as an IV infusion in a clinic. The FDA has not approved ketamine for any psychiatric condition.
- Legal status
- Schedule III controlled substance. Legal with a prescription in every state. Psychiatric use is off-label, which is lawful but means the FDA has not reviewed it for that purpose.
- Cost
- Two October 2026 surveys of prices posted by U.S. clinics found a median of $450 to $475 per IV infusion, with posted prices from $250 to $950, and a median of roughly $2,700 to $2,900 for a six-infusion series.
Evidence by condition
- DepressionControlled trials
Trials show rapid antidepressant effects in people who had not responded to other treatment. An expert consensus statement notes small study sizes and limited data on long-term benefit and safety.
Access, sessions, risks and sources
How it is accessed
Prescribed by a licensed clinician. Given in clinics by IV infusion or injection. Some telehealth companies prescribe compounded tablets or lozenges for home use; federal rules allowing controlled substances to be prescribed by telemedicine without an in-person visit currently run through December 31, 2026, and the FDA has warned about the risks of compounded ketamine taken without on-site monitoring.
What sessions look like
In a clinic, an infusion typically takes about 40 to 60 minutes, followed by observation until the effects wear off. Clinics commonly sell a first course as a series of six infusions.
Studied for
- Treatment-resistant depression
- Other mood and anxiety disorders (limited data)
Known risks
- Sedation and dissociation (feeling detached from your body or surroundings)
- Increases in blood pressure
- Slowed breathing (respiratory depression)
- Urinary tract and bladder problems
- Psychiatric side effects, and potential for abuse and misuse
Who should be cautious
- People with high blood pressure or heart or blood-vessel disease, because ketamine raises blood pressure
- People with a history of substance misuse
- People with a history of psychosis
- Anyone considering compounded ketamine at home without a health care provider monitoring them
Sources
- Warning on compounded ketamine for psychiatric disorders (October 2023) (U.S. Food and Drug Administration)(opens in a new tab)
- Drug scheduling (U.S. Drug Enforcement Administration)(opens in a new tab)
- A consensus statement on the use of ketamine in the treatment of mood disorders (2017) (JAMA Psychiatry)(opens in a new tab)
- Telemedicine prescribing flexibilities extended through 2026 (U.S. Department of Health and Human Services)(opens in a new tab)
- Ketamine therapy prices published by U.S. clinics (October 2026) (KetamineHQ price survey)(opens in a new tab)
- Ketamine and Spravato cost analysis (fourth quarter 2026) (Signal Hill Strategies price survey)(opens in a new tab)